These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 26966785)

  • 41. Antioxidant Therapy in Graves' Orbitopathy.
    Lanzolla G; Marcocci C; Marinò M
    Front Endocrinol (Lausanne); 2020; 11():608733. PubMed ID: 33381085
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Graves' orbitopathy].
    Eckstein A; Möller L; Führer D; Oeverhaus M
    Dtsch Med Wochenschr; 2021 Oct; 146(20):1344-1351. PubMed ID: 34644795
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment options for Graves' orbitopathy.
    Marcocci C; Altea MA; Leo M
    Expert Opin Pharmacother; 2012 Apr; 13(6):795-806. PubMed ID: 22404364
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Diagnosis and treatment of dysthyroid orbitopathy: a multidisciplinary disease].
    Leray B; Imbert P; Thouvenin D; Boutault F; Caron P
    J Fr Ophtalmol; 2013 Dec; 36(10):874-85. PubMed ID: 24239215
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effects of Rituximab on Graves'orbitopathy: A retrospective study of 14 patients.
    Eid L; Coste-Verdier V; Longueville E; Ribeiro E; Nicolescu-Catargi B; Korobelnik JF
    Eur J Ophthalmol; 2020 Sep; 30(5):1008-1013. PubMed ID: 31025590
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Future Prospects for the Treatment of Graves' Hyperthyroidism and Eye Disease.
    Neumann S; Place RF; Krieger CC; Gershengorn MC
    Horm Metab Res; 2015 Sep; 47(10):789-96. PubMed ID: 26197854
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low-Dose Rituximab for Active Moderate to Severe Graves' Orbitopathy Resistant to Conventional Treatment.
    Du Pasquier-Fediaevsky L; Andrei S; Berche M; Leenhardt L; Héron E; Rivière S
    Ocul Immunol Inflamm; 2019; 27(5):844-850. PubMed ID: 29652204
    [No Abstract]   [Full Text] [Related]  

  • 48. Clinical Features of Graves' Ophthalmopathy and Impact of Enalapril on the Course of Mild Graves' Ophthalmopathy: A Pilot Study.
    Ataabadi G; Dabbaghmanesh MH; Owji N; Bakhshayeshkaram M; Montazeri-Najafabady N
    Endocr Metab Immune Disord Drug Targets; 2020; 20(1):139-148. PubMed ID: 31345156
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Management of Graves' ophthalmopathy.
    Wiersinga WM
    Nat Clin Pract Endocrinol Metab; 2007 May; 3(5):396-404. PubMed ID: 17452966
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reactivation of Graves' orbitopathy after rehabilitative orbital decompression.
    Baldeschi L; Lupetti A; Vu P; Wakelkamp IM; Prummel MF; Wiersinga WM
    Ophthalmology; 2007 Jul; 114(7):1395-402. PubMed ID: 17320178
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pediatric aspects in Graves' orbitopathy.
    Gogakos AI; Boboridis K; Krassas GE
    Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():234-44. PubMed ID: 20467370
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Graves' Orbitopathy: Current Concepts for Medical Treatment.
    Oeverhaus M; Stöhr M; Möller L; Führer D; Eckstein A
    Klin Monbl Augenheilkd; 2021 Jan; 238(1):24-32. PubMed ID: 33506447
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of tanshinone IIA in an in vitro model of Graves' orbitopathy.
    Rhiu S; Chae MK; Lee EJ; Lee JB; Yoon JS
    Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):5900-10. PubMed ID: 25159204
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Selenium in Graves Hyperthyroidism and Orbitopathy.
    Marinò M; Menconi F; Rotondo Dottore G; Leo M; Marcocci C
    Ophthalmic Plast Reconstr Surg; 2018; 34(4S Suppl 1):S105-S110. PubMed ID: 29933354
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Practical Guidelines Management of Graves Ophthalmopathy.
    Subekti I; Soewondo P; Soebardi S; Darmowidjojo B; Harbuwono DS; Purnamasari D; Tarigan TJE; Wisnu W; Tahapary DL; Kurniawan F; Sidik M; Nusanti S; Dewiputri S; Suharko H; Suardana GG; Suroyo I; Wulani V; Siswoyo AD; Gondhowiardjo S; Kodrat H
    Acta Med Indones; 2019 Oct; 51(4):364-371. PubMed ID: 32041923
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel observational study protocol to develop a prediction model that identifies patients with Graves' ophthalmopathy insensitive to intravenous glucocorticoids pulse therapy.
    Wang Y; Wang H; Li L; Li Y; Sun J; Song X; Zhou H
    BMJ Open; 2021 Dec; 11(12):e053173. PubMed ID: 34916318
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pediatric Graves' ophthalmopathy: the pre- and postpubertal experience.
    Holt H; Hunter DG; Smith J; Dagi LR
    J AAPOS; 2008 Aug; 12(4):357-60. PubMed ID: 18359653
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Natural course of mild Graves' orbitopathy: is it a chronic remitting or a transient disease?
    Anagnostis P; Boboridis K; Adamidou F; Kita M
    J Endocrinol Invest; 2017 Mar; 40(3):257-261. PubMed ID: 27664101
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Orbital decompression in Graves' orbitopathy: efficacy and safety.
    Goh MS; McNab AA
    Intern Med J; 2005 Oct; 35(10):586-91. PubMed ID: 16207257
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Superior ophthalmic vein thrombosis: A rare complication of Graves' orbitopathy.
    Sorrentino D; Taubenslag KJ; Bodily LM; Duncan K; Stefko T; Yu JY
    Orbit; 2018 Jun; 37(3):175-178. PubMed ID: 29053044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.